ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 23.5 TWD -0.63% Market Closed
Market Cap: 18.6B TWD
Have any thoughts about
ScinoPharm Taiwan Ltd?
Write Note

ScinoPharm Taiwan Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ScinoPharm Taiwan Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
ScinoPharm Taiwan Ltd
TWSE:1789
Gross Profit
NT$1.3B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
-4%
Y
YungShin Global Holding Corp
TWSE:3705
Gross Profit
NT$3.2B
CAGR 3-Years
-4%
CAGR 5-Years
-2%
CAGR 10-Years
3%
Formosa Laboratories Inc
TWSE:4746
Gross Profit
NT$2.1B
CAGR 3-Years
28%
CAGR 5-Years
22%
CAGR 10-Years
12%
S
SCI Pharmtech Inc
TWSE:4119
Gross Profit
NT$347.4m
CAGR 3-Years
-19%
CAGR 5-Years
-17%
CAGR 10-Years
-3%
Lotus Pharmaceutical Co Ltd
TWSE:1795
Gross Profit
NT$9.3B
CAGR 3-Years
19%
CAGR 5-Years
20%
CAGR 10-Years
22%
Standard Chem & Pharm Co Ltd
TWSE:1720
Gross Profit
NT$2.9B
CAGR 3-Years
14%
CAGR 5-Years
12%
CAGR 10-Years
8%
No Stocks Found

ScinoPharm Taiwan Ltd
Glance View

Market Cap
18.6B TWD
Industry
Pharmaceuticals

ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.

Intrinsic Value
16.51 TWD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is ScinoPharm Taiwan Ltd's Gross Profit?
Gross Profit
1.3B TWD

Based on the financial report for Jun 30, 2024, ScinoPharm Taiwan Ltd's Gross Profit amounts to 1.3B TWD.

What is ScinoPharm Taiwan Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
-4%

Over the last year, the Gross Profit growth was 18%.

Back to Top